Home › Funds › venBio Partners LLC › ALXO
venBio Partners LLC position in ALXO
ALX ONCOLOGY HLDGS INC · Health Care
venBio Partners LLC reported holding 12,884,638 shares of ALXO (ALX ONCOLOGY HLDGS INC) in its Q2 2026 13F filing — a position valued at US$26.7M, representing 5.14% of its reported portfolio and ranking #5 among its reported holdings. venBio Partners LLC has disclosed ALXO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How venBio Partners LLC's ALXO position evolved
venBio Partners LLC first disclosed a stake in ALXO in Q3 2023 at 9,699,925 shares (US$46.6M). The position peaked in Q4 2023 at 9,699,925 shares, worth US$144.4M. Across 12 filings, venBio Partners LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 12,884,638 shares valued at US$26.7M. Notable position changes include a 33% increase in Q1 2026 (shares rose 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 9.70M | $46.56M | New |
| Q4 2023 | 9.70M | $144.43M | Hold |
| Q1 2024 | 9.70M | $108.15M | Hold |
| Q2 2024 | 9.70M | $58.49M | Hold |
| Q3 2024 | 9.70M | $17.65M | Hold |
| Q4 2024 | 9.70M | $16.20M | Hold |
| Q1 2025 | 9.70M | $6.04M | Hold |
| Q2 2025 | 9.70M | $4.03M | Hold |
| Q3 2025 | 9.70M | $17.75M | Hold |
| Q4 2025 | 9.70M | $10.96M | Hold |
| Q1 2026 | 12.88M | $25.83M | Add |
| Q2 2026 | 12.88M | $26.67M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALXO and 13F data
ALXO (ALX ONCOLOGY HLDGS INC) is a Health Care company. 35 other funds we track also report a position in ALXO — the largest reported positions include Redmile Group, LLC (US$15.3M), SILVERARC CAPITAL MANAGEMENT, LLC (US$11.9M), TCG Crossover Management, LLC (US$11.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALXO
- Redmile Group, LLC 7.39M sh · $15.30M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 5.74M sh · $11.89M · Q2 2026
- TCG Crossover Management, LLC 5.66M sh · $11.71M · Q2 2026
- Vivo Capital, LLC 3.18M sh · $6.59M · Q2 2026
- 5AM Venture Management, LLC 3.06M sh · $6.33M · Q2 2026
- Almitas Capital LLC 2.94M sh · $6.08M · Q2 2026
More on venBio Partners LLC
FAQ
How long has venBio Partners LLC held ALXO?
venBio Partners LLC has disclosed ALXO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is venBio Partners LLC's current position in ALXO?
As of Q2 2026, venBio Partners LLC holds 12.88M shares of ALXO (ALX ONCOLOGY HLDGS INC), valued at $26.67M, representing 5.14% of its reported portfolio and ranking #5.
Has venBio Partners LLC been buying or selling ALXO?
In the latest 13F filing (Q2 2026), venBio Partners LLC held unchanged its position in ALXO. The position peaked in Q4 2023 at 9.70M shares.
Which other funds hold ALXO?
Other major institutional holders of ALXO include Redmile Group, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, TCG Crossover Management, LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.